X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
female (19) 19
oncology (17) 17
breast cancer (15) 15
cancer (12) 12
index medicus (12) 12
middle aged (11) 11
aged (10) 10
breast neoplasms - drug therapy (10) 10
chemotherapy (10) 10
adult (9) 9
breast neoplasms - pathology (9) 9
care and treatment (8) 8
research (7) 7
aged, 80 and over (6) 6
apoptosis (6) 6
treatment outcome (6) 6
women (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
article (5) 5
metastasis (5) 5
neoplasm staging (5) 5
radiation therapy (5) 5
breast neoplasms - radiotherapy (4) 4
breast neoplasms - surgery (4) 4
drug administration schedule (4) 4
health aspects (4) 4
hematology, oncology and palliative medicine (4) 4
oncology, experimental (4) 4
patients (4) 4
radiotherapy (4) 4
tamoxifen (4) 4
toxicity (4) 4
trastuzumab (4) 4
analysis (3) 3
animals (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast neoplasms - metabolism (3) 3
breast neoplasms - mortality (3) 3
breast neoplasms - therapy (3) 3
clinical trials (3) 3
clinical trials as topic (3) 3
disease-free survival (3) 3
docetaxel (3) 3
follow-up studies (3) 3
kaplan-meier estimate (3) 3
mastectomy, segmental (3) 3
medicine & public health (3) 3
metastatic breast-cancer (3) 3
raloxifene (3) 3
randomized-trial (3) 3
surgery (3) 3
surgical adjuvant breast (3) 3
survival (3) 3
tamoxifen - therapeutic use (3) 3
time factors (3) 3
tumors (3) 3
abridged index medicus (2) 2
adjuvant chemotherapy (2) 2
administration, oral (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
anticancer therapy (2) 2
antineoplastic agents, hormonal - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
breast boost (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - prevention & control (2) 2
cancer cells (2) 2
carcinomas (2) 2
cell biology (2) 2
cell cycle arrest (2) 2
cell line, tumor (2) 2
chemotherapy, adjuvant (2) 2
clinical-trials (2) 2
combined modality therapy (2) 2
confidence intervals (2) 2
conservation therapy (2) 2
conserving surgical-procedures (2) 2
deoxycytidine - analogs & derivatives (2) 2
diagnosis (2) 2
disease progression (2) 2
diseases (2) 2
dose-response relationship, drug (2) 2
efficacy (2) 2
estrogen (2) 2
fractionation (2) 2
gemcitabine (2) 2
hypofractionation (2) 2
induced apoptosis (2) 2
infusions, intravenous (2) 2
internal medicine (2) 2
lapatinib (2) 2
lpa receptors (2) 2
lumpectomy (2) 2
male (2) 2
mammary glands (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 10/2019, Volume 394, Issue 10206, pp. 1323 - 1323
Bins and Mathijssen highlight that, in both our study and the CheckMate 141 trial,4 subgroup analyses by choice of chemotherapy revealed higher hazard ratios... 
Schedules | Human papillomavirus | Chemotherapy | Pembrolizumab | Cell death | Clinical trials | Methotrexate | Survival | Patients | Subgroups | Quality of life | Apoptosis
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 09/2017, Volume 165, Issue 2, p. 375
Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer... 
Antimitotic agents | Care and treatment | Relapse | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Antineoplastic agents | Cancer | Diseases
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 09/2011, Volume 20, Issue 10 Supplement, pp. A105 - A105
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 14, pp. 1564 - 1573
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. TPS9597 - TPS9597
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2017, Volume 165, Issue 2, pp. 375 - 382
Journal Article
Current Breast Cancer Reports, ISSN 1943-4588, 3/2011, Volume 3, Issue 1, pp. 55 - 62
Trastuzumab was first described over 25 years ago and was approved for clinical use a decade ago. Since then, marked improvement in survival in patients with... 
Neratinib (HKI-272) | Trastuzumab resistance | Medicine & Public Health | Trastuzumab-DM1 | Internal Medicine | Oncology | HER-2/neu | Metastatic breast cancer | Lapatinib | Surgical Oncology | HER-2 | Trastuzumab | Tyrosine | Care and treatment | Breast cancer | Metastasis | Health aspects | Cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 84, Issue 4, pp. 888 - 893
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2007, Volume 68, Issue 2, pp. 347 - 353
Journal Article